TY - JOUR T1 - African-American Race and Mortality in Interstitial Lung Disease: A Multicenter Propensity-Matched Analysis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00255-2018 SP - 1800255 AU - Ayodeji Adegunsoye AU - Justin M. Oldham AU - Shashi K. Bellam AU - Jonathan H. Chung AU - Paul A. Chung AU - Kathleen M. Biblowitz AU - Steven Montner AU - Cathryn Lee AU - Scully Hsu AU - Aliya N. Husain AU - Rekha Vij AU - Gokhan Mutlu AU - Imre Noth AU - Matthew M. Churpek AU - Mary E. Strek Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/05/10/13993003.00255-2018.abstract N2 - We studied whether African-American race is associated with younger age and decreased survival time at diagnosis of interstitial lung disease (ILD).We performed a multicenter, propensity score matched analysis of patients with an ILD diagnosis followed at five US hospitals between 2006–2016. African-Americans were matched with patients of other races based on a time-dependent propensity score calculated from multiple patient, physiologic, diagnostic, and hospital characteristics. Multivariable logistic regression models were used. All-cause mortality and hospitalisations were compared between race-stratified patient cohorts with ILD, and sensitivity analyses were performed.The study included 1,640 patients with ILD, 13% of whom were African-American, followed over 5,041 person-years. When compared with patients of other races, African-Americans with ILD were younger at diagnosis (56 years vs. 67 years), but in the propensity-matched analyses had greater survival (HR=0.46; 95%CI=0.28–0.77; P=0.003) despite similar risk of respiratory hospitalisations (RR=1.04; 95%CI=0.83–1.31; P=0.709), and similar GAP-ILD (gender-age-physiology-ILD) scores at study entry. Sensitivity analyses in a separate cohort of 9503 patients with code-based ILD diagnosis demonstrated a similar association of baseline demographic characteristics with all-cause mortality.We conclude that African-Americans demonstrate a unique phenotype associated with younger age at ILD diagnosis and perhaps longer survival time.African-American subjects with interstitial lung disease are younger, less likely to be male and may have greater survival time than other racial groups, despite similar risk of respiratory hospitalisation, and GAP-ILD (gender-age-physiology-ILD) scoresFootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of Interest Disclosures: Drs. Adegunsoye, Chung JH, Montner, Lee, Bellam, Chung P, Biblowitz, along with Ms. Hsu, have nothing to disclose. Dr. Oldham has received speaking and advisory board fees from Genentech and Boehringer Ingelheim. Dr. Vij has received a grant from Genentech to study the genomics of autoimmune interstitial lung diseases. Dr. Noth has received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and BI for the conduct of clinical trials in IPF. Dr. Strek has received institutional funding for interstitial lung disease research from Boehringer-Ingelheim, Genentech, Gilead and MedImmune and has served on an advisory board for Boehringer-Ingelheim. Dr. Churpek is supported by a career development award from the National Heart, Lung, and Blood Institute (K08 HL121080), has received honoraria from Chest for invited speaking engagements and also has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients.Conflict of interest: Dr. Adegunsoye has nothing to disclose.Conflict of interest: Dr. Oldham received speaking and advisory board fees from Genentech and Boehringer Ingelheim.Conflict of interest: Dr. Bellam has nothing to disclose.Conflict of interest: Dr. Chung has nothing to disclose.Conflict of interest: Dr. Chung has nothing to disclose.Conflict of interest: Dr. Biblowitz has nothing to disclose.Conflict of interest: Dr. Montner has nothing to disclose.Conflict of interest: Dr. Lee has nothing to disclose.Conflict of interest: Ms. Hsu has nothing to disclose.Conflict of interest: Dr. Husain has nothing to disclose.Conflict of interest: Dr. Vij received a grant from Genentech to study the genomics of autoimmune interstitial lung diseases.Conflict of interest: Dr. Mutlu has nothing to disclose.Conflict of interest: Dr. Noth received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and BI for the conduct of clinical trials in IPF. .Conflict of interest: Dr. Churpek is supported by a career development award from the National Heart, Lung, and Blood Institute (K08 HL121080), has received honoraria from Chest for invited speaking engagements and also has a patent pending (ARCD. P0535US.P2) for risk stratification algorithms for hospitalized patients.Conflict of interest: Dr. Strek received institutional funding for interstitial lung disease research from Genentech, Gilead and MedImmune and she serves on a data monitoring committee for Boehringer Ingelheim. ER -